Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend

Bulletin Express

08/13

Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.

The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).

The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1146232852"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146232852\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1146232852?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 17:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146232852","market":"us","top_or_hot":-1,"title":"Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.</p>\n<p>The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).</p>\n<p>The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-13 17:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.</p>\n<p>The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).</p>\n<p>The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"銀諾醫藥-B","start_time":0,"source_url":"","article_id":"1146232852","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146232852","pubTimestamp":1786612181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"广州英诺健制药定于 8 月 25 日召开董事会会议，批准 2026 年上半年业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.\nThe meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).\nThe announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}